Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

BACKGROUND: The phase III MONARCH randomized controlled trial (NCT02332590) demonstrated that in patients with rheumatoid arthritis (RA), sarilumab (anti-interleukin-6 receptor monoclonal antibody) monotherapy is superior to adalimumab monotherapy in reducing disease activity and signs and symptoms...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Res Ther
Main Authors: Strand, Vibeke, Gossec, Laure, Proudfoot, Clare W. J., Chen, Chieh-I, Reaney, Matthew, Guillonneau, Sophie, Kimura, Toshio, van Adelsberg, Janet, Lin, Yong, Mangan, Erin K., van Hoogstraten, Hubert, Burmester, Gerd R.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6009058/
https://ncbi.nlm.nih.gov/pubmed/29921318
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-018-1614-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados